Sign In
NewsRadar

Search Press
Looking for press releases of a particular company? Enter company name (or keyword) here.

   


Pantec Biosolutions receives ISO 13485 certification


Ruggell, Liechtenstein, 24 September 2008, Pantec Biosolutions AG, a privately-owned company developing innovative technologies for transdermal drug delivery, today announced that it has successfully established a Quality Management System (QMS) in accordance with ISO 13485:2003 standards for medical devices. In order to achieve ISO standards, Pantec Biosolutions implemented a QMS for its operations to ensure consistent quality of the Company’s products under development. The Company was audited by Swiss TS Technical Services AG and was awarded quality management certifications under MDD 93/42/EWG for the design, development, manufacturing and distribution of laser-based medical devices.

“By achieving ISO accreditation, Pantec Biosolutions can now offer full quality assurance in terms of product development and production of laser-based medical devices”, stated Dr. Christof Boehler, CEO of Pantec Biosolutions. “We are currently aiming to further develop our drug delivery platform by implementing only the highest standards of international quality and extending these standards to all aspects of our business.”

About Pantec Biosolutions and P.L.E.A.S.E.®

Pantec Biosolutions is a private drug delivery company specialised in using laser microporation technology to deliver large molecular weight drugs into the epidermis for local or systemic uptake. Its proprietary P.L.E.A.S.E.® (Painless Laser Epidermal System) platform enables efficient, needle-free and painless administration of biopharmaceutical drugs, in varying and individualised dosages, through partnered patch technology. The technology is currently in clinical trials for the delivery of IVF hormone therapy, a market with an estimated value of US$1.5 – 2 billion.

Pantec Biosolutions’ P.L.E.A.S.E.® platform is available both for the development of the Company’s own pipeline and for penetration into new markets through strategic partnerships. Pantec Biosolutions is based in Ruggell, Liechtenstein.

Further Information:

Dr. Christof Boehler
CEO
Pantec Biosolutions AG
t: +423 377 7800
e: christof.boehler@pantec-biosolutions.com

Douglas Pretsell
Account Director
College Hill Life Sciences
t: +49 (0)89 57 00 18 06
e: douglas.pretsell@collegehill.com


Publisher Contact Information:

Pantec Biosolutions
+423 377 7800
christof.boehler@pantec-biosolutions.com

Company profile of Pantec Biosolutions
Past press releases of Pantec Biosolutions.

Data


26,581
Tech investments
From our Online Data Service
17,166
VC-backed companies
From our Radar


Recent Deals


DATEAMOUNTSECTOR
Nov 25€24.0MInternet commerce
Jan 17N/AIT services
Jan 17€7.4MInternet commerce
Jan 16€100.0MConsumer electronics
Jan 16€23.0MBiotechnology
Jan 15€1.2MEnergy related
Jan 15€28.0MKnowledge management

For information on Europe's most extensive database on technology funding click here!

Events



Press Releases


May 28
Identiq
identiq raises $5m seed, launches privacy-first identity validation...

Apr 29
Nethone
nethone raised over $1 million from innovation nest

Oct 1
The Link App
the link app launches version 2.0

Mar 29
Addex Therapeutics
addex sucessfully raises chf40 million in capital increase

Jan 2
Urban Jungle
urban jungle raises £1m in seed funding to build tech-enabled home ...





About usContact usLegal Information
Copyright © 1999-2019
Emerging Technology Research Europe Inc. All rights reserved.